186 related articles for article (PubMed ID: 34646386)
61. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
Pang J; Wang S; Liao L; Liu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
[TBL] [Abstract][Full Text] [Related]
62. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
Filho OM; Stover DG; Asad S; Ansell PJ; Watson M; Loibl S; Geyer CE; Bae J; Collier K; Cherian M; O'Shaughnessy J; Untch M; Rugo HS; Huober JB; Golshan M; Sikov WM; von Minckwitz G; Rastogi P; Maag D; Wolmark N; Denkert C; Symmans WF
JAMA Oncol; 2021 Apr; 7(4):603-608. PubMed ID: 33599688
[TBL] [Abstract][Full Text] [Related]
63. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
[TBL] [Abstract][Full Text] [Related]
64. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Candelaria RP; Spak DA; Rauch GM; Huo L; Bassett RL; Santiago L; Scoggins ME; Guirguis MS; Patel MM; Whitman GJ; Moulder SL; Thompson AM; Ravenberg EE; White JB; Abuhadra NK; Valero V; Litton J; Adrada BE; Yang WT
Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S35-S41. PubMed ID: 34272161
[TBL] [Abstract][Full Text] [Related]
65. Ultrasonography for endoleak detection after endoluminal abdominal aortic aneurysm repair.
Abraha I; Luchetta ML; De Florio R; Cozzolino F; Casazza G; Duca P; Parente B; Orso M; Germani A; Eusebi P; Montedori A
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD010296. PubMed ID: 28598495
[TBL] [Abstract][Full Text] [Related]
66. Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy.
Ang J; Hu L; Huang PT; Wu JX; Huang LN; Cao CH; Zheng YX; Chen L
World J Gastroenterol; 2012 Dec; 18(47):7026-32. PubMed ID: 23323004
[TBL] [Abstract][Full Text] [Related]
67. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.
Du F; Wang W; Wang Y; Li M; Zhu A; Wang J; Cai R; Ma F; Fan Y; Li Q; Zhang P; Todorovic V; Yuan P; Xu B
Breast Cancer Res Treat; 2020 Jul; 182(1):67-77. PubMed ID: 32394350
[TBL] [Abstract][Full Text] [Related]
68. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
[TBL] [Abstract][Full Text] [Related]
69. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim SB; Sohn J; Im SA; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
Ann Oncol; 2020 May; 31(5):569-581. PubMed ID: 32278621
[TBL] [Abstract][Full Text] [Related]
70. The effect of ultrasound pulse length on microbubble cavitation induced antibody accumulation and distribution in a mouse model of breast cancer.
Amate M; Goldgewicht J; Sellamuthu B; Stagg J; Yu FTH
Nanotheranostics; 2020; 4(4):256-269. PubMed ID: 33033688
[TBL] [Abstract][Full Text] [Related]
71. Potential application value of Doppler ultrasonography in neoadjuvant chemotherapy for breast cancer.
Santos DW; Fernandes PC; Guedes CA; Debs Diniz AL
Minerva Ginecol; 2016 Aug; 68(4):405-11. PubMed ID: 27302212
[TBL] [Abstract][Full Text] [Related]
72. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
Gerber B; Loibl S; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Nekljudova V; Untch M; von Minckwitz G;
Ann Oncol; 2013 Dec; 24(12):2978-84. PubMed ID: 24136883
[TBL] [Abstract][Full Text] [Related]
73. Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer.
Adrada BE; Candelaria R; Moulder S; Thompson A; Wei P; Whitman GJ; Valero V; Litton JK; Santiago L; Scoggins ME; Moseley TW; White JB; Ravenberg EE; Yang WT; Rauch GM
Cancer; 2021 Aug; 127(16):2880-2887. PubMed ID: 33878210
[TBL] [Abstract][Full Text] [Related]
74. Evaluating pathologic response of breast cancer to neoadjuvant chemotherapy with computer-extracted features from contrast-enhanced ultrasound videos.
Zhang Q; Yuan C; Dai W; Tang L; Shi J; Li Z; Chen M
Phys Med; 2017 Jul; 39():156-163. PubMed ID: 28690116
[TBL] [Abstract][Full Text] [Related]
75. Ultrasound Improves the Delivery and Therapeutic Effect of Nanoparticle-Stabilized Microbubbles in Breast Cancer Xenografts.
Snipstad S; Berg S; Mørch Ý; Bjørkøy A; Sulheim E; Hansen R; Grimstad I; van Wamel A; Maaland AF; Torp SH; Davies CL
Ultrasound Med Biol; 2017 Nov; 43(11):2651-2669. PubMed ID: 28781149
[TBL] [Abstract][Full Text] [Related]
76. Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
Ademuyiwa FO; Chen I; Luo J; Rimawi MF; Hagemann IS; Fisk B; Jeffers G; Skidmore ZL; Basu A; Richters M; Ma CX; Weilbaecher K; Davis J; Suresh R; Peterson LL; Bose R; Bagegni N; Rigden CE; Frith A; Rearden TP; Hernandez-Aya LF; Roshal A; Clifton K; Opyrchal M; Akintola-Ogunremi O; Lee BH; Ferrando-Martinez S; Church SE; Anurag M; Ellis MJ; Gao F; Gillanders W; Griffith OL; Griffith M
Breast Cancer Res Treat; 2021 Aug; 189(1):187-202. PubMed ID: 34173924
[TBL] [Abstract][Full Text] [Related]
77. PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to predict partial response in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery.
Testa AC; Ferrandina G; Moro F; Pasciuto T; Moruzzi MC; De Blasis I; Mascilini F; Foti E; Autorino R; Collarino A; Gui B; Zannoni GF; Gambacorta MA; Valentini AL; Rufini V; Scambia G
Ultrasound Obstet Gynecol; 2018 May; 51(5):684-695. PubMed ID: 28620930
[TBL] [Abstract][Full Text] [Related]
78. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.
Kern P; Kalisch A; von Minckwitz G; Pütter C; Kolberg HC; Pott D; Kurbacher C; Rezai M; Kimmig R
J Chemother; 2016 Jun; 28(3):210-7. PubMed ID: 26239282
[TBL] [Abstract][Full Text] [Related]
79. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
80. A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature.
Warram JM; Sorace AG; Saini R; Umphrey HR; Zinn KR; Hoyt K
J Ultrasound Med; 2011 Jul; 30(7):921-31. PubMed ID: 21705725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
